You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
凱普生物(300639.SZ)擬對凱普醫學檢驗增資並同步實施員工及專家跟投
格隆匯 12-01 20:49

格隆匯 12 月 1日丨凱普生物(300639.SZ)公佈,公司為加快自身做大做強步伐,對凱普醫學檢驗進行增資並同步實施員工及專家跟投方案,從而激發公司內生動力與活力,提升治理水平與競爭力。公司將參與此次增資。此次增資完成後,公司仍為凱普醫學檢驗的控股股東。

此次擬將凱普醫學檢驗註冊資本由5億元增加至6億元,其中,公司以1.4億元認繳凱普醫學檢驗新增註冊資本7000萬元,公司骨幹員工及專家隊伍以合計不超過6000萬元認繳凱普醫學檢驗新增註冊資本3000萬元。根據對凱普醫學檢驗未來發展的預期,結合凱普醫學檢驗目前的財務狀況,確定增資價格為2.00元/股。員工及專家跟投將以包括但不限於有限合夥企業等組織形式投入。

凱普醫學檢驗對公司第三方醫學檢驗業務進行統一投資和管理。公司通過第三方醫學檢驗所的建設在全國全面鋪設第三方醫學檢驗服務網絡,將公司業務向下遊產業鏈擴展,實現“儀器+試劑+服務”的一體化經營模式。此次公司與凱普醫學檢驗新增股東對凱普醫學檢驗進行增資,有利於增強凱普醫學檢驗的資本實力,提升其管理能力和服務水平,符合公司長期發展戰略。實施員工及專家跟投方案,從而激發公司內生動力與活力,提升治理水平與競爭力。此次增資完成後,公司持有凱普醫學檢驗的股權比例為70.78%,凱普醫學檢驗仍納入公司合併報表範圍。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account